Navigation Links
VeriStrat® Results Correlate with Survival Outcomes in Kidney Cancer Patients
Date:10/14/2011

BROOMFIELD, Colo., Oct. 14, 2011 /PRNewswire/ -- Data presented at the 10th International Kidney Cancer Symposium being held in Chicago, IL show that the pretreatment blood-based test, VeriStrat, was able to stratify renal cell carcinoma (RCC) patients treated with a combination of two targeted therapies, sunitinib (Sutent®) and erlotinib (Tarceva®), by survival outcomes.   Patients who tested VeriStrat Good had significantly longer progression free survival (PFS) and overall survival (OS) when treated with the combination therapy as compared to patients who tested VeriStrat Poor.  

The study retrospectively, and in a fully blinded fashion, applied the VeriStrat test to a subset of the patient population from a Phase I/II clinical trial of erlotinib plus sunitinib in RCC patients.  VeriStrat analysis was performed on all available serum samples.   Thirty-seven of 46 patients were classified as either VeriStrat Good or VeriStrat Poor based on the VeriStrat algorithm developed for non-small cell lung cancer (NSCLC).

The analysis showed that VeriStrat Good patients had a significantly longer PFS and OS versus VeriStrat Poor patients (PFS: median 12.3 vs. 4.7 months, log-rank p=0.025 and OS: median 38.4 vs. 11.6 months, log-rank p=0.045).   There was a statistically significant correlation between VeriStrat classification and Heng prognostic criteria, but not MSKCC classification.   VeriStrat showed the potential to further refine current grouping of RCC patients, separating MSKCC intermediate patients into VeriStrat Good and VeriStrat Poor subgroups with statistically significantly different PFS (log-rank p = 0.030).

Heinrich Roder, D.Phil., Chief Technology Officer of Biodesix stated, "This data set shows that our test, VeriStrat, may be helpful in identifying specific and useful disease characteristics in RCC.   It is also exciting to see that our test is showing utility across multiple solid tumors.   Oncologists currently do not have a simple serum test that can be used across multiple tumor types.   We are continuously engaging in additional studies to further explore the full clinical utility of VeriStrat."

About VeriStrat
VeriStrat is a serum proteomic test currently available for patients with advanced NSCLC.  The test identifies patients who are likely to have good or poor outcomes after treatment with epidermal growth factor receptor inhibitors (EGFRIs).  Samples are processed in Biodesix' CLIA accredited laboratory and results are typically reported within 72 hours of sample shipment.  VeriStrat has been validated in clinical studies with over 1500 patients.  For more information on VeriStrat or to order VeriStrat, visit www.VeriStratSupport.com or call the VeriStrat Support Hotline at 1-866-432-5930.

About Biodesix
Biodesix is a personalized medicine company focused on the development of diagnostic products that inform treatment decisions and improve patient care.  The Company's goal is to give physicians more information about the patient and their disease; understanding the clinically meaningful information contained within each patient's molecular profile leads to better care and better outcomes.  The Company's unique approach is based on ProTS®, proprietary technology which exploits the power of mass spectrometry and enables the discovery of specific molecular profiles.  Biodesix collaborates with clinical investigators to address critical clinical questions, and partners with biotechnology and pharmaceutical companies to develop diagnostics to select patients most likely to benefit from novel therapies.  For more information about Biodesix, please visit www.Biodesix.com.

Sutent® is a registered trademark of Pfizer Inc.
Tarceva® is a registered trademark of OSI Pharmaceuticals, LLC, a member of the Astellas Pharma Global Development Inc. group of companies.

This press release contains statements that are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the Company's inability to further identify, develop and achieve commercial success for products and technologies; the risk that the Company's financial resources will be insufficient to meet the Company's business objectives; uncertainties relating to the regulatory approval process and changes in relationships with strategic partners. We disclaim any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Biodesix
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VeriStrat® Test Identifies Lung Cancer Patients Benefiting from Combination Therapy
2. Perrigo Company Will Release First Quarter Fiscal 2012 Results On October 27, 2011
3. Masimo to Report Third Quarter 2011 Financial Results After Market Close on October 25, 2011
4. Cumberland Pharmaceuticals to Announce Third Quarter 2011 Financial Results on November 3, 2011
5. Renessa® Treatment for Stress Incontinence: Three Year Clinical Results Presented
6. Quest Diagnostics to Release Third Quarter 2011 Financial Results
7. Southern Home Medical Achieves Strong Third Quarter Results
8. Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology
9. Ultra Clean to Announce Third Quarter Results
10. NxStage® to Report Third Quarter Fiscal 2011 Financial Results
11. Amylin Pharmaceuticals to Webcast Third Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... MOUNTAIN VIEW, Calif. , Dec. 8, 2016 ... it intends to offer newly issued shares of common stock, ... "Shares") pursuant to an underwritten public offering.  The final terms ... at the time of pricing, and there can be no ... completed. IRIDEX expects to use the net proceeds ...
(Date:12/8/2016)... -- Australia Glaucoma Surgery Devices Market Outlook to ... Glaucoma Surgery Devices Market Outlook to 2022", provides ... Devices market. The report provides value, in millions ... prices (USD) within market segement - Glaucoma Drainage ... and distribution shares data for each of these ...
(Date:12/8/2016)...  The global biosurgery market is expected to grow ... of 2016 to 2021. The market is poised to ... billion in 2016. The market is primarily driven by ... injuries and spinal problems, increasing clearance of biosurgery products ... loss management. In this report, the biosurgery ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital Tampa Wound ... Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the ... hospitals and facilities have earned this distinction. This is the second time the ...
(Date:12/8/2016)... Pennsylvania (PRWEB) , ... December 08, 2016 , ... ... Duck Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which ... , “This was our first franchise-wide Quack Gives Back initiative, ...
(Date:12/8/2016)... and JENNERSVILLE, Pa. (PRWEB) , ... December 08, ... ... that Penn Medicine Southern Chester County, a Property owned by an affiliate of ... million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s ... groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced ... J. Hennessy, Jr said, “CURE Media Group is honored to team up with Upstage ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the ... series, and attorneys from the firm’s global Life Sciences & Medical Technology Group have ...
Breaking Medicine News(10 mins):